The resurgence of the US Biosecure Act is creating ripples in the global pharmaceutical landscape, particularly for Indian contract development and manufacturing organizations (CDMOs). Nuvama Institutional Equities recently highlighted the revised draft bill, emphasizing its shift in focus from Chinese companies to a broader spectrum of entities of concern. This change, embedded within the National Defense Authorization Act, presents a five-year transition period for innovators to disengage from existing contracts with flagged companies.
The altered tone of the Biosecure Act is perceived as a positive development for Indian CDMOs, as it could potentially lead to a renewed trend of global supply chain diversification. The previous iteration of the Act had prompted global innovators to explore alternatives to Chinese outsourcing, resulting in increased project allocations to Indian firms. With the reintroduction of discussions around the Biosecure Act, Nuvama anticipates a similar pattern to unfold, bolstering the position of Indian CDMOs in the international market.
Nuvama’s analysis points to Divi’s Laboratories as a primary beneficiary of this evolving landscape, thanks to its growth-oriented capital expenditure strategies and expanding footprint in the GLP-1 domain. Additionally, Neuland Laboratories, recently integrated into Nuvama’s CDMO coverage, and Jubilant Pharmova, gearing up to launch its third CDMO line in the US during the latter half of FY26, are poised to capitalize on the potential opportunities arising from the Act. The brokerage also highlights Aurigene, Syngene, and Aurobindo Pharma’s upcoming biologics CMO unit as prospective beneficiaries amidst the shifting dynamics of pharmaceutical outsourcing.
While the revised Biosecure Act appears to be more tempered compared to its previous version, the underlying emphasis on bolstering supply chain security outside of China remains clear. US-based innovators are expected to continue seeking partnerships beyond Chinese borders, a trend that could sustain the visibility and relevance of Indian CDMOs in the global pharmaceutical arena. Nuvama reiterates its ‘Buy’ recommendation for Divi’s Laboratories, Neuland Laboratories, and Jubilant Pharmova, underscoring the potential growth prospects for these entities in light of the evolving regulatory environment.
Key Takeaways:
– The US Biosecure Act’s revival could have a positive impact on Indian CDMOs, fostering supply chain diversification.
– Divi’s Laboratories, Neuland Laboratories, and Jubilant Pharmova are positioned as key beneficiaries of the evolving regulatory landscape.
– Indian CDMOs stand to gain prominence as US innovators prioritize supply chain security outside of China.
– Continued focus on partnerships with non-Chinese entities may enhance opportunities for Indian pharmaceutical manufacturers.
– Nuvama Institutional Equities maintains a ‘Buy’ stance on select Indian CDMOs, anticipating growth in the wake of the Biosecure Act’s resurgence.
In conclusion, the resurgence of the Biosecure Act and its revised approach signal a potential shift in the dynamics of pharmaceutical outsourcing, particularly favoring Indian CDMOs. As global innovators seek to fortify their supply chains beyond China, Indian manufacturers are poised to play an increasingly pivotal role in meeting international pharmaceutical demands. The evolving regulatory landscape presents opportunities for growth and expansion for companies such as Divi’s Laboratories, Neuland Laboratories, and Jubilant Pharmova, positioning them favorably in the competitive global market of contract development and manufacturing organizations.
Tags: biotech
Read more on businesstoday.in